This February, we're excited to shine our Clovertex Target of the Month spotlight on the estrogen receptor (ER). ER is a critical driver of ER positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer, a condition characterized by the cancer cells growing in response to the hormone estrogen. In an exciting update, Arvinas, Inc., together with Pfizer Inc., shared the news that vepdegestrant (ARV-471) has snagged the FDA Fast Track designation. This groundbreaking PROTAC is on a mission to degrade ER in patients with ER+/HER2- breast cancer that's either locally advanced or metastatic, specifically those who've already received endocrine-based treatments. This makes vepdegestrantYet another degrader receiving FDA Fast Track designation makes this space incredibly hot, signaling a growing recognition of the potential for these therapies
The featured rendering displays the crystal structure of GDC-0927 bound to estrogen receptor alpha (PDB entry 6PFM).
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
1. Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
2. Clovertex website